Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16913
Title: Inhibiting system xC− and glutathione biosynthesis – a potential Achilles' heel in mutant-p53 cancers
Authors: Clemons, Nicholas J;Liu, David S;Duong, Cuong P;Phillips, Wayne A
Issue Date: 5-Jul-2017
Citation: Molecular & Cellular Oncology 2017; 4(5): e1344757
Abstract: Effective therapeutic strategies to target mutant tumor protein p53 (TP53, best known as p53) cancers remain an unmet medical need. We found that mutant p53 impairs the function of nuclear factor (erythroid-derived 2)-like 2 (NFE2L2, commonly known as NRF2), suppresses solute carrier family 7 member 11 (SLC7A11) expression, and diminishes cellular glutamate/cystine exchange. This decreases glutathione biosynthesis, resulting in redox imbalance. Mutant p53 tumors are thus inherently susceptible to further perturbations of the SLC7A11/glutathione axis.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16913
DOI: 10.1080/23723556.2017.1344757
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/29057306
Type: Journal Article
Subjects: APR-246
NFE2L2
NRF2
PRIMA-1met
SLC7A11
glutathione (GSH)
p53
reactive oxygen species (ROS)
system xC−
xCT
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.